Are we understanding the respiratory effects of traffic related airborne particles?

trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med 2004;170:377–82. 5. Ferrer J, Montes JF, Villarino MA, et al. Influence of particle size on extrapleural talc dissemination after talc slurry pleurodesis. Chest 2002;122:1018–27. 6. Kennedy L, Harley RA, Sahn SA, et al. Talc slurry pleurodesis. Pleural fluid and histologic analysis. Chest 1995;107:1707–12. 7. Werebe EC, Pazetti R, Milanez DC Jr, et al. Systemic distribution of talc after intrapleural administration in rats. Chest 1999;115:190–3. 8. Dresler CM, Olak J, Herndon JE, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 2005;127:909–15. 9. Wagenfeld L, Zeitz O, Richard G. Visual loss after povidone-iodine pleurodesis. N Engl J Med 2007;357:1264–5. 10. Olivares-Torres CA, Laniado-Laborin R, ChavezGarcia C, et al. Iodopovidone pleurodesis for recurrent pleural effusions. Chest 2002;122:581–3. 11. Janssen JP, Collier G, Astoul P, et al. Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet 2007;369:1535–9. 12. Lee YC, Teixeira LR, Devin CJ, et al. Transforming growth factor-beta2 induces pleurodesis significantly faster than talc. Am J Respir Crit Care Med 2001;163:640–4. 13. Lee YC, Lane KB, Parker RE, et al. Transforming growth factor beta(2) (TGF beta(2)) produces effective pleurodesis in sheep with no systemic complications. Thorax 2000;55:1058–62. 14. Lee YC, Yasay JR, Johnson JE, et al. Comparing transforming growth factor-beta2, talc and bleomycin as pleurodesing agents in sheep. Respirology 2002;7:209–16. 15. Light RW, Cheng DS, Lee YC, et al. A single intrapleural injection of transforming growth factorbeta(2) produces an excellent pleurodesis in rabbits. Am J Respir Crit Care Med 2000;162:98–104. 16. Kishi K, Homma S, Sakamoto S, et al. Efficacious pleurodesis with OK-432 and doxorubicin against malignant pleural effusions. Eur Respir J 2004;24:263–6. 17. Luh KT, Yang PC, Kuo SH, et al. Comparison of OK432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. A randomized trial. Cancer 1992;69:674–9. 18. Ren S, Terman DS, Bohach G, et al. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer. Chest 2004;126:1529–39. 19. Tremblay A.Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest 2006;129:362–8. 20. Tremblay A, Mason C, Michaud G. Use of tunnelled catheters for malignant pleural effusions in patients fit for pleurodesis. Eur Respir J 2007;30:759–62. 21. Musani AI, Haas AR, Seijo L, et al. Outpatient management of malignant pleural effusions with small-bore, tunneled pleural catheters. Respiration 2004;71:559–66. 22. Putnam JB Jr, Walsh GL, Swisher SG, et al. Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter. Ann Thorac Surg 2000;69:369–75. 23. Saffran L, Ost DE, Fein AM, et al. Outpatient pleurodesis of malignant pleural effusions using a small-bore pigtail catheter. Chest 2000;118:417–21.